Utilizing massively parallel combinatorial searches and AI algorithms to unleash the full power of RNAi. RNAi is a Nobel-prize-winning discovery that enables the repression of disease-causing genes, using small interfering RNA molecules (siRNA). These molecules are by nature digital, discrete, and highly specific to an active site. Their chemical topology naturally lends itself to combinatorial searches and AI algorithms, which become particularly powerful and predictive when combined with cost-effective DNA synthesis and sequencing technologies. Our platform leverages massively-parallel processes to map the chemical space and reveal the structure-activity relationship (SAR) of RNAi molecules. Employing big data, we optimize every component of siRNA molecules, including their safety, efficiency, and duration of effect. With hundreds of millions of respiratory disease patients in need of a cure, the lungs are the next frontier for RNAi therapeutics. While there are many broad applications for our platform, we are currently focused on developing the next generation of RNAi therapeutics to silence the disease-causing genes that are responsible for respiratory illnesses. In this process, we take a principled human genetics approach to our target selection, enabling our fully-programmable RNAi molecules to precisely eliminate the root causes of such diseases. We appreciate the interest that our valued partners and funders have found in our technologies. the development of therapies typically relies on a slow process of trial and error. At Eleven Tx, we orchestrate these technologies into highly-efficient processes for mapping the vast combinatorial space of potential RNAi molecules and precisely program the next generation of RNAi therapeutics. Capitalizing on these capabilities, we create tailor-made therapeutics that precisely silence disease-causing genes, treating the root cause of illnesses in humans.
B2B
26 to 50
Seed
$26.3M
Scaling Up
2020
Research & Consulting Services
Optimize Every Component of siRNA
Cost-Effective DNA Synthesis
Reveal Structure- Activity Relationship
Increase Efficiency
Increase Productivity
Analytics
Service
Yes
Active
Machine Learning
Natural Language Processing
Software
Senior Data Scientist
Remote , Remote
Senior Scientist - RNA Biology
Remote , Remote
AI/ML Professionals
Want to work at Eleven Therapeutics?
We can introduce you to the right person at Eleven Therapeutics
6
1
$22M
Company was founded 2020 and it took almost 2 years (Aug 2022) to raise first external round
Investors
Interested in researching Eleven Therapeutics?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Eleven Therapeutics
Yaniv Erlich
Chief Executive Officer
Shaul Ilan
Co-Founder / COO & BD
Roei Pinhas
Director of Finance
Potential Customers
Interested in what they do or partnership?
Learn more about how they work